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Abstract
Prion diseases are fatal neurodegenerative disorders caused by aberrant metabolism of the cellular prion protein (PrP
C). In
genetic forms of these diseases, mutations in the globular C-terminal domain are hypothesized to favor the spontaneous
generation of misfolded PrP conformers (including the transmissible PrP
Sc form) that trigger downstream pathways leading
to neuronal death. A mechanistic understanding of these diseases therefore requires knowledge of the quality control
pathways that recognize and degrade aberrant PrPs. Here, we present comparative analyses of the biosynthesis, trafficking,
and metabolism of a panel of genetic disease-causing prion protein mutants in the C-terminal domain. Using quantitative
imaging and biochemistry, we identify a misfolded subpopulation of each mutant PrP characterized by relative detergent
insolubility, inaccessibility to the cell surface, and incomplete glycan modifications. The misfolded populations of mutant
PrPs were neither recognized by ER quality control pathways nor routed to ER-associated degradation despite
demonstrable misfolding in the ER. Instead, mutant PrPs trafficked to the Golgi, from where the misfolded subpopulation
was selectively trafficked for degradation in acidic compartments. Surprisingly, selective re-routing was dependent not only
on a mutant globular domain, but on an additional lysine-based motif in the highly conserved unstructured N-terminus.
These results define a specific trafficking and degradation pathway shared by many disease-causing PrP mutants. As the
acidic lysosomal environment has been implicated in facilitating the conversion of PrP
C to PrP
Sc, our identification of a
mutant-selective trafficking pathway to this compartment may provide a cell biological basis for spontaneous generation of
PrP
Sc in familial prion disease.
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Introduction
Several diseases are caused by mutations that generate aberrant
proteins with adverse cytotoxic consequences [1]. Analysis of the
biosynthesis, maturation, processing, trafficking and metabolism of
the aberrant protein generated in these diseases is instrumental in
identifying the mechanisms underlying pathogenesis. Disease-
causing mutations can result in misfolded proteins that are rapidly
(and sometimes inappropriately) eliminated by cellular quality
control (QC) pathways. In other instances, mutants fail to be
efficiently recognized by QC and consequently accumulate
excessively. In both situations, the interaction between mutant
proteins and QC machinery has emerged as a critical determinant
of disease pathogenesis. Therefore, mechanistic analyses of mutant
protein metabolism have consistently provided insights into
cellular QC pathways whose age-dependent failure is increasingly
implicated in various degenerative diseases [2].
For proteins transiting the secretory pathway, the major QC
pathways reside in the ER [3]. Considerable insight into ER
quality control has come from the analysis of both artificial and
naturally occurring mutant proteins. The sum of these studies has
led to three general themes. First, multiple QC pathways operate
in parallel to recognize different subsets of client proteins. Second,
recognition of misfolded proteins is typically mediated by
chaperones. Third, the features that distinguish folded from
misfolded proteins usually involve exposure of residues or domains
(e.g., unpaired cysteines or hydrophobic patches) inappropriate for
the environment. While other sites of QC in the secretory pathway
have also been proposed, they have been poorly studied [3,4].
Collectively, these multiple QC systems deal with a remarkably
wide range of substrates. Failure to recognize and appropriately
triage a mutated protein may underlie many dominantly inherited
gain-of-function protein misfolding diseases. Thus, an understand-
ing of the pathogenic mechanisms requires knowledge of the QC
pathway(s) that are normally engaged by the aberrant mutant
protein.
Prion diseases are one example of disorders in which the
generation of aberrant misfolded proteins has dire consequences
for the cell. These neurodegenerative diseases can be acquired by
a transmissible route, sporadically, or through an inherited
mutation. In each case, the central event involves aberrant
metabolism of the cell surface prion protein (PrP) [5]. In
transmissible prion diseases, a misfolded conformer of PrP (termed
PrP
Sc) directs the templated conversion of normal cellular PrP into
additional PrP
Sc. How or why PrP
Sc accumulation leads to
neurodegeneration remains largely unknown. A primary obstacle
to such studies is the difficulty in classifying cellular alterations as
causes, direct consequences or secondary adaptations to PrP
Sc
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investigate inherited mutations, where the root cause of the
disease, a specific mutation in PrP, is established [6]. By
determining the effect of the mutation on PrP metabolism,
potential events that lead to cellular dysfunction can be identified.
This type of approach has already shed light on the mechanism
of pathogenesis of a subset of inherited PrP mutations that occur
within the central hydrophobic domain of the protein. These
mutations cause increased generation of a transmembrane form of
PrP termed
CtmPrP [7]. Elevated
CtmPrP levels can lead to
neurodegeneration in both mouse models and humans [7],
illuminating one pathway of PrP-mediated cytotoxicity that may
even have a broader role in transmissible disease [8]. More
generally, these studies led to the discovery that some N-terminal
ER translocation signals are intrinsically inefficient [9], may be
regulated [10,11], and could contribute to neurodegeneration
[12], illustrating the utility of mutant protein analyses in
uncovering broader principles in cell biology.
Interestingly, however, most inherited mutations do not occur
within the hydrophobic region, but in the globular C-terminal
domain [6]. The mechanism(s) by which such mutations cause
disease is not known. These mutations can, in principle, affect
many different aspects of PrP metabolism or function. Numerous
(and sometimes conflicting) aberrations have been described for
individual mutations studied in a wide range of experimental
systems [13–23]. In some instances, different populations of the
same mutant protein are metabolized by different pathways,
neither of which is normal [15]. In other cases, different studies
examining the same or related mutants come to diametrically
opposite conclusions about what is aberrant [16,24]. Thus, the
conclusions from these mutant studies are rather diverse and range
from no identifiable effects [25,26] to nearly quantitative and
dramatically abnormal processing [13,27], sometimes for the same
mutant. Which, if any, of these alterations might actually
contribute to disease progression versus representing innocuous
or even adaptive changes, remains difficult to discern. These
observations are further confounded by the fact that only a minor
subpopulation of the mutant protein is likely to display altered
cellular behavior under normal conditions (given the late-onset of
disease), with the major population showing wild type properties.
Yet, these minor populations, over long time periods in post-
mitotic cells, can nonetheless have significant physiologic conse-
quences in vivo. The challenge therefore is to identify subtle and
sometimes minor deviations from normal PrP metabolism that
might be a contributing factor in disease.
To address this problem, we have initiated a systematic and
quantitative comparison of multiple inherited mutations within the
C-terminal globular domain of PrP. Our focus was on identifying
the ways that cells distinguish and differentially handle wild type
versus mutant PrPs. We reasoned that deviations shared by many
or all of the mutants may represent the cellular quality control
response to aberrant PrP species. A clear delineation of these
pathways is almost certainly of direct relevance to the associated
diseases. Not only would such analyses identify the routes of
mutant PrP trafficking, but also provide strong candidates for
pathways that, when perturbed, would lead to accumulation of
aberrant PrP. Indeed, age-dependent decline in QC and
degradation pathways is emerging as a common theme in many
neurodegenerative diseases, underscoring the importance of
defining their role in PrP metabolism. In this study, our analysis
has led to the identification of an intracellular trafficking pathway
that is shared by several mutant PrPs to selectively route misfolded
species for degradation in lysosomes. Interestingly, this misfolded
mutant PrP-specific trafficking pathway is dependent not only on
the C-terminal mutation but on a highly conserved lysine-based
motif in the N-terminus of PrP. These data highlight an
unappreciated role for post-ER quality control in PrP metabolism
and further suggest important hypotheses for the mechanisms
underlying prion disease pathogenesis.
Results
Subtle differences in steady state localization patterns of
wild type and mutant PrPs
Wild type human PrP (wtPrP) and several human disease-
causing PrP mutants were expressed in mouse N2a cells and
selectively visualized by indirect immunofluorescence with the
human-specific 3F4 PrP antibody (Fig. 1A–B). As expected, wtPrP
was found predominantly on the cell surface, with varying
amounts of an intracellular pool in the ER, Golgi, and endosomal
system (Fig. S1A). This pattern is consistent with PrP trafficking
through the secretory pathway en route to the cell surface, its
constitutive recycling through the endosomal system, and its
eventual degradation in lysosomes. This same general pattern was
seen in all cells regardless of expression level, although there was
some heterogeneity in the relative amounts found in each of the
different cellular compartments (Fig. S1A). All PrP mutants also
showed localization in the same compartments, including the ER,
Golgi, endosomes and the cell surface (Fig. S1B). A panel of
representative cells, all at comparable expression levels, illustrates
the generally similar patterns of localization for wtPrP and each of
the mutants (Fig. 1B).
Among the mutants analyzed, PrP(A117V) was most similar to
wtPrP not only in its general pattern of localization, but also in the
relative amounts seen in the different cellular compartments. This
is consistent with the fact that this mutation is not located within
the structured globular C-terminal domain and therefore does not
influence the folding of PrP, but is instead known to influence the
topology of a small subset (,5%) of total PrP in vivo [7,28]. Other
mutations within the central hydrophobic domain that influence
topology [PrP(G114V) and PrP(G131V)] also had no discernable
Author Summary
Prion diseases are transmissible fatal neurodegenerative
diseases caused by aberrant metabolism of the cellular
prion protein (PrP
C). The transmissible agent is PrP
Sc,a




Sc can be generated de novo in inherited
prion diseases due to synthesis of aberrant PrP forms from
a mutated PrP gene. Such mutant PrP forms, analogous to
other aberrant proteins, should typically be destroyed by
various cellular ‘quality control’ (QC) pathways; however,
several human diseases result from an eventual break-
down in these QC systems, often due to prolonged
bombardment by mutant proteins. We have therefore
sought to identify the specific pathways that normally
cope with disease-causing misfolded PrPs. By carefully
following the generation and turnover of these mutant
PrPs in cells, we have discovered an intracellular QC
pathway that selectively routes biochemically aberrant PrP
species to lysosomes. As the lysosomal system has been
implicated as a site for conversion of PrP
C to PrP
Sc, our
identification of a mutant-selective trafficking pathway to
this compartment may provide a cell biological basis for
spontaneous generation of PrP
Sc in familial prion disease.
Importantly, these findings suggest that eventual changes
or breakdown of this QC pathway may contribute to
disease progression.
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mutants within the globular C-terminal domain, while displaying
the same qualitative pattern of localization, appeared to have a
somewhat different relative distribution of PrP among the different
compartments. For example, the most obvious case in this
experiment is PrP(H187R), where in most cells, the relative
intensity of the perinuclear intracellular fluorescence was similar to
or greater than that on the cell surface. While cells with this type of
distribution were sometimes seen for wtPrP (Fig. S1A), they were
much less prevalent. Conversely, cells with nearly exclusive cell
surface localization were seen less frequently in PrP(H187R) than
wtPrP cells. A similar subtle shift in distribution was also noted for
each of the other globular domain mutants, although as with
PrP(H187R), this was not a property of every cell. Qualitatively
similar effects of these mutants were also observed in HeLa and
MDCK cell lines (unpublished observations), indicating that the
consequences of these mutations were not species or cell type
specific.
Further support for a different relative distribution was provided
by analysis of cells co-expressing fluorescently tagged wtPrP and
PrP(H187R). Consistent with the analyses of non-tagged proteins,
wtPrP-CFP and PrP(H187R)-YFP displayed largely overlapping
patterns of localization (Fig. 1C). However, quantitative analysis of
their relative ratios in different cellular regions (see the quantitative
ratiometric image, Fig. 1C) revealed a clear difference in the peri-
nuclear intracellular population. While the ratio of wtPrP-
CFP:PrP(H187R)-YFP was ,1:1 at the cell surface, this ratio
ranged between ,2:1 to ,10:1 in the intracellular peri-nuclear
regions. The overall ratio within the entire intracellular region
was, on average, ,3:1. Therefore, both proteins appeared to
occupy largely the same cellular locales, albeit with different ratios.
These regional differences in ratio could not simply be explained
by different fluorescence properties of CFP versus YFP, as co-
expression of PrP(H187R)-CFP with PrP(H187R)-YFP showed a
much more uniform ratiometric image (Fig. 1C). In addition,
exchanging the fluorescent tags on the wt and mutant PrPs still
showed increased intracellular fluorescence from the mutant, while
co-expression of differently tagged wtPrPs in the same cell showed
a relatively uniform ratio of fluorescence throughout (data not
shown). Thus, although both wtPrP and PrP(H187R) seem to
sample the same cellular regions, they differ in their relative
distribution among at least some intracellular compartments.
This difference occurred within the secretory pathway (i.e., after
PrP translocation into the ER), as cells blocked in ER-to-Golgi
transport with Brefeldin A showed identical, exclusively ER
localization patterns for both wtPrP and PrP(H187R) (Fig. S1C).
Consistent with this result, in vitro translocation analysis of all of
these mutants showed that their import efficiency into the ER was
unaffected ([28] and our unpublished results). Only the mutations
within the hydrophobic domain [PrP(G114V), PrP(A117V), and
PrP(G131V)] showed an effect on translocation, resulting in
slightly increased generation of a topological variant,
CtmPrP ([7]
and our unpublished results). Together, these observations indicate
that the globular domain mutants are qualitatively similar to
wtPrP in their ER import, trafficking, and degradation, leading to
a very similar pattern of cellular distribution. Nonetheless,
differential ratios of the wt and mutant PrPs in certain
compartments suggested an effect of the mutations on some
aspect of PrP trafficking and/or degradation at a step after
translocation into the ER.
Quantitative single-cell analyses reveal differential
mutant PrP localization
The heterogeneity of localization patterns seen with both wtPrP
and the mutants, combined with their largely overlapping
distributions, precluded clear and direct qualitative comparisons.
The co-expression analyses (Fig. 1C), while instructive in detecting
a difference between the surface and intracellular populations,
were potentially confounded by the presence of fluorescent tags,
the possibility of alterations in trafficking due to interactions
between wt and mutant PrP, and any differences in the absolute
expression levels of wt and mutant PrPs. We therefore turned to
quantitative analyses of populations of randomly chosen single
cells expressing untagged wtPrP or each of the PrP mutants.
Individual cells, chosen randomly and imaged at an arbitrary
1 mm thick confocal section (at mid-nuclear level), were quantified
for total, intracellular, and cell surface fluorescence (see Fig. S2).
The percentage of total fluorescence (within this confocal section)
located intracellularly was then plotted against expression level for
each cell (Fig. 2A–C).
When analyzed in this manner, wtPrP showed a wide
distribution (ranging from ,5% to 60%) with an average of
,28% intracellular PrP (Fig. 2A–C). Surprisingly, this distribution
remained almost entirely unaffected by expression level over a very
broad range (,20-fold), suggesting that the normal biosynthetic,
trafficking, and degradation pathways for PrP are not easily
saturable. PrP(A117V) showed an almost identical distribution,
and no statistically significant differences from wtPrP could be
discerned (Fig. 2C). By contrast, each of the globular domain
mutants displayed several differences from wtPrP [PrP(H187R)
and PrP(E200K) are shown in Fig. 2A and 2B]. First, the overall
intracellular population was statistically higher [,56% and ,52%
for PrP(H187R) and PrP(E200K) respectively, relative to ,28%
for wtPrP]. Second, expression-dependent increases in the
intracellular population could be observed. When binned into
low, medium, and high expressing cells, the PrP mutants showed a
statistical difference in the amount of intracellular PrP between the
low and high level expressing cells (,44% versus ,74%
intracellular PrP in cells expressing PrP(H187R) at low or high
levels respectively). Importantly however, even among the lowest
expressing cells (estimated to be close to physiologic levels of PrP),
the mutants remained discernable from wtPrP. Consistent with the
qualitative observations, substantial overlap in distribution could
be observed between the wtPrP and mutant cells, particularly at
the low and medium expression levels.
It is noteworthy that the absolute proportion of intracellular PrP
changed among different experiments and appeared to be
influenced by culture conditions (e.g., batches of serum, age of
cells, relative confluence, and time after transfection). Despite this
variability, the relative differences among the mutants remained
reproducibly consistent when sufficient numbers of cells were
analyzed. Shown in Fig. 3 is the tabulated data from a single
Figure 1. Steady state localization of wtPrP and various disease-causing mutants. (A) Indirect immunofluorescent localization of PrP using
the 3F4 antibody in N2a cells transiently transfected with wtPrP or any of 7 different PrP mutants. Identical detector settings were used to image
representative fields of cells. (B) Enlarged images of single cells chosen from the corresponding fields from panel A illustrate the overall subtle
differences in localization of C-terminal mutant PrPs compared to wtPrP and PrP(A117V). (C) Cells co-expressing fluorescently tagged wtPrP and
PrP(H187R) were imaged. Pseudocolored depiction of the mutant:wt fluorescence ratio in different cellular locales is shown in the last panel (scale is
below the image).
doi:10.1371/journal.ppat.1000479.g001
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labeled and quantified on a cell-by-cell basis (as detailed in Fig. S2) to determine the percent of total fluorescence found in intracellular compartments.
This value (% intracellular) is plotted against expression level, with each point representing an individual cell. Data collected from a single representative
experiment is shown. Vertical dashed lines demarcate the boundaries of low, medium and high PrP expression levels that were used to bin cells for
statistical analysis. The mean intracellular PrP levels (%) for each of these expression levels is listed for both wtPrP and PrP(H187R). Asterisks indicate
statistical significance from wtPrP for points falling within the respective expression levels (p,10
24,p ,10
27, and p,10
216 at low, medium, and high
expression levels, respectively). (B) Analysis performed as in panel A, but for PrP(E200K). (C) Analysis of PrP(A117V) as in panel A. Note that the entire
experiment (panels A–C) was performed at the same time, and that the wtPrP data points are included in each graph for comparison.
doi:10.1371/journal.ppat.1000479.g002
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consistently decreased surface-to-intracellular ratio among each
of the globular domain mutants, but not PrP(A117V). The wide
heterogeneity among cells, the effect of different culture condi-
tions, the expression level-dependence of localization patterns, and
the substantial overlap in distribution between wtPrP and the
mutants are likely to explain the previously diverse (and sometimes
conflicting) results regarding the effects of PrP mutants. Indeed,
many of the previous localization patterns (ER, aggregates, Golgi,
etc.) were readily observed in our experiments in subpopulations of
cells, emphasizing the importance of more quantitative population
studies in identifying overall systematic differences.
Biochemical identification of a mutant-specific
subpopulation of PrP
The differential steady-state distribution of globular domain
mutants suggested the presence of a mutant-selective subpopula-
tion that was either trafficked or metabolized differently than
wtPrP, resulting in its intracellular localization. To identify and
biochemically characterize this population, we analyzed PrP in
detergent lysates of N2a cells expressing either wtPrP or the
different mutants. In a typical experiment, wtPrP and PrP(H187R)
recovered in the detergent soluble fraction (using 0.5% Triton X-
100 and 0.5% deoxycholate) showed little or no differences in the
glycosylation pattern or isoforms (Fig. 4A; ‘‘S’’ lanes). However,
slightly less mutant PrP was consistently observed in the soluble
fraction. This detergent soluble wtPrP or PrP(H187R) was
quantitatively lost if the intact cells were treated with extracellular
trypsin prior to analysis (Fig. 4A). This indicates that the
population of wtPrP and mutant PrP on the cell surface share
similar solubilization properties and are comparably glycosylated.
By contrast, the detergent insoluble fraction (Fig. 4A; ‘‘P’’ lanes)
showed an increase in the PrP isoforms recovered from cells
expressing PrP(H187R) versus wtPrP. This insoluble mutant PrP
population was intracellular because it was protected from
extracellular trypsin added to intact cells (Fig. 4A), but completely
digested under the same conditions if cells were permeabilized
with detergent (Fig. 4B). The relative amount of this insoluble
PrP(H187R) varied based on expression level (consistent with the
imaging data in Fig. 2) and culture conditions such that higher
expression levels correlated with increased amounts of insoluble,
intracellular forms (Fig. S3A and S3B). In some experiments, only
a very small proportion of PrP(H187R) was recovered in the
insoluble fraction, but in all instances, this was consistently greater
than that seen with wtPrP (Fig. S3C). The PrP isoform
preferentially enriched in the insoluble fraction of cells expressing
PrP(H187R) relative to wtPrP was glycosylated, but not fully
modified. By contrast, the unglycosylated isoform of PrP (which
likely represents the small proportion that failed to enter the ER
[29]) was recovered to a comparable extent for both wtPrP and
PrP(H187R). The glycosylated PrP(H187R) in the insoluble
fraction was mostly (but not entirely) resistant to digestion with
endoglycosidase H (EndoH), but not PNGase (Fig. 4C). This
suggests that the majority of detergent-insoluble PrP(H187R) had
been processed by Golgi enzymes. Thus, the mutant-specific
subpopulation of PrP(H187R), distinguishable by its relative
detergent insolubility, is in a post-ER intracellular compartment
as had been anticipated by the localization analyses. Its differential
glycosylation relative to the major cell surface population further
argues for its altered trafficking or processing.
Similar analyses of several other globular domain mutants
revealed the existence of an increased population (to varying
extents in different experiments) of detergent-insoluble, trypsin
inaccessible (intracellular), incompletely glycosylated, EndoH-
resistant isoforms (Fig. 4D, 4E, and data not shown). In each
case, the increase in this species came at the expense of fully
mature, detergent soluble forms when expression levels and film
exposure times were carefully matched. By contrast, each of the
Figure 3. All globular domain PrP mutants display altered localization. Cells expressing wtPrP and the indicated mutants were stained,
imaged and analyzed as in Fig. 2. The surface:intracellular ratio of PrP is plotted for each of the mutants for comparison with wtPrP. Data points
represent individual cells from a single representative experiment. All mutants were analyzed together on the same day. Horizontal black bars
indicate the mean values for each data set. Each mutant dataset was compared to wtPrP by the Student’s t-test and found to be statistically
significant in all cases (p,10
28), except PrP(A117V).
doi:10.1371/journal.ppat.1000479.g003
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species with these characteristics, consistent with their essentially
normal localization pattern when analyzed by immunofluores-
cence. This mutant-specific biochemical species therefore likely
corresponds to the differentially localized subpopulation observed
in live cells and identified by the single-cell quantitative analyses.
Indeed, biochemical features (including relative detergent insolu-
bility) that are shared by multiple prion protein mutants has been
previously observed, albeit with a different cell line and different
PrP mutants from those in our study [13]. In addition to the
EndoH-resistant population of each mutant, a variable amount of
detergent-insoluble EndoH-sensitive population was also some-
times observed (Fig. 4C and 4E). This might represent an ER-
localized subpopulation of the mutant PrPs that is slightly delayed
in its exit to the Golgi [24]. Alternatively, it is possible that glycan
trimming on mutant PrPs is either somewhat slower or less
efficient than for wild type PrP, leading to an EndoH-sensitive
population. Regardless of the explanation, the post-ER EndoH-
resistant population is the predominant mutant-specific species
observed, consistent with the imaging results in Fig. 1.
Several of the mutants were also analyzed in HeLa cells, a
completely unrelated human cell line that expresses very low (but
detectable) levels of endogenous PrP. As in N2a cells, PrP(H187R)
and PrP(E200K) expressed in HeLa cells showed increased
amounts of detergent-insoluble, incompletely glycosylated, intra-
cellular forms (Fig. 5A). This increase was typically accompanied
by a reduction of the fully mature detergent-soluble species, and
was especially evident for some mutants (e.g., E200K). The
detergent-insoluble mutant-specific population was mostly (but not
entirely) resistant to deglycosylation with EndoH (Fig. 5B),
indicating its primarily post-ER localization. Thus, unlike the
highly species-specific nature of prion-templated conversion from
PrP
C to PrP
Sc, the folding, trafficking, and metabolism of PrP
mutants appears to be more generally conserved. This is consistent
with intracellular protein trafficking and metabolism being
mediated by very generic and highly conserved machinery.
Furthermore, the finding of similar results in two cell lines that
express different amounts and species (human versus mouse) of
endogenous PrP suggests that the behavior of PrP mutants may
not be significantly influenced by the co-expressed wild type
counterpart. Indeed, in the short term of our experiments, the
presence or absence of endogenous PrP in co-expression
experiments (e.g., as in Fig. 1C) did not seem to influence mutant
PrP localization. Whether the converse effect occurs (of mutant
PrP altering wild type PrP properties) is unclear from our studies,
but seems plausible given that PrP can interact with itself. Earlier
observations suggest such an effect [23], and would be consistent
with the dominant nature of disease inheritance.
Figure 4. Biochemical identification of a mutant-specific subpopulation of misfolded PrP. (A) Detergent lysates from cells expressing
wtPrP or PrP(H187R) were separated into soluble (S) and insoluble (P) fractions, resolved by SDS-PAGE and immunoblotted using the 3F4 antibody.
The cells were either analyzed directly (untreated) or first digested with 100 mg/ml of extracellular trypsin to remove cell surface proteins prior to lysis.
The migration of different PrP species are indicated on the left: Mat=mature PrP with the full complement of complex glycans; Imm=immature PrP
with core glycans; 2CHO=unglycosylated PrP. (B) Cells expressing PrP(H187R) were either left untreated (U), digested with 100 mg/ml of extracellular
trypsin (T), or digested with trypsin in the presence of 0.2% Triton X-100 detergent (T/D) before harvesting for SDS-PAGE and immunoblotting. (C)
Detergent lysates from cells expressing wtPrP or PrP(H187R) were digested with EndoH (E) or with PNGase (P) or left untreated (2), prior to analysis
by SDS-PAGE and immunoblotting for PrP. The lower panel shows this blot stripped and re-probed with an antibody against an ER resident
glycoprotein, TRAPa. (D) Cells expressing wtPrP or each of 10 PrP mutants were digested with extracellular trypsin, harvested in detergent, separated
into soluble (S) and insoluble (P) fractions, and analyzed by immunoblotting. For comparison, one-fourth the amount of total untreated (U) cell lysate
is shown. (E) Analysis of the indicated PrP mutants by glycosidase digestions as in panel C.
doi:10.1371/journal.ppat.1000479.g004
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Altered localization, detergent-insolubility, and incomplete
glycan modification are all indirect indicators of protein misfold-
ing. To directly assess whether the specific subpopulation of
mutant PrPs that display these characteristics are indeed folded
differently, we employed limited trypsin digestion (Fig. 6). In this
experiment, total detergent lysates from PrP-expressing cells were
treated on ice with increasing concentrations of trypsin, followed
by separation into soluble and insoluble fractions. As expected,
essentially all mature wild type PrP was completely in the
supernatant fraction, and this population was highly sensitive to
trypsin. By contrast, unglycosylated PrP (presumably a cytosolic
form that is folded differently) was quantitatively in the insoluble
fraction and showed notably more trypsin resistance. A small
amount of immature glycosylated PrP was also seen in the
insoluble fraction and displayed modest trypsin resistance. The
differences in trypsin sensitivity among the different PrP forms
illustrates the utility of this assay in discriminating among them.
When mutant PrPs were analyzed by this assay, each one
displayed clear differences from the wild type (Fig. 6). Most
notably, a higher proportion of the mutant PrPs were found in the
insoluble fraction as incompletely glycosylated forms (as charac-
terized in Fig. 4 and 5). This species in each mutant was
preferentially resistant to trypsin compared to the highly sensitive
fully glycosylated soluble species from the same mutant. The
unglycosylated species of each mutant showed comparable
resistance to the unglycosylated species of wild type PrP,
suggesting that this form is similarly folded regardless of the
mutation. We can conclude from this analysis that by the measure
of limited protease accessibility, the immaturely glycosylated and
detergent-insoluble species that is enriched in each mutant is
folded differently than the soluble fully mature species of either
wild type PrP or the mutants.
It is worth emphasizing that detergent insolubility and trypsin
resistance should not be taken to necessarily indicate aggregation.
Rather, these are simply convenient assays that allow enrichment
of this species of PrP which, due to its altered folding by as yet
undefined ways, causes a change in its biochemical properties.
Similar differences in detergent solubility have been described
before for some PrP mutants [13,14,21,23] and could represent
residence in different membrane environments. Indeed, as
described in subsequent sections, the efficient ER exit, accessibility
to glycosidases, and the absence of punctate structures by imaging
all argue against a grossly aggregated or insoluble species in vivo.
Spatio-temporal analysis of mutant PrP trafficking
To determine the origin of the mutant-specific intracellular
subpopulation of PrP, we turned to pulse-chase analyses. Upon
pulse labeling transfected cells for 10 minutes with
35S-methio-
nine, wtPrP is synthesized in three forms corresponding to
unglycosylated (,25%), singly-glycosylated (,25%), and doubly-
glycosylated (,50%) PrP (Fig. 7A). Upon chase for 30 minutes,
the glycosylated forms were trimmed to a slightly smaller
molecular weight species (consistent with mannosidase action in
the cis-Golgi), and matured to higher molecular weight complex
glycosylated species, consistent with transit through the Golgi
Figure 5. Analysis of PrP mutants in HeLa cells. (A) Wild type PrP, PrP(H187R) and PrP(E200K) were expressed in HeLa cells and analyzed for
detergent solubility and surface trypsin digestion as in Figure 4. Mock-transfected cells were also analyzed in parallel. Very long exposures of the blot
revealed low level endogenous PrP expression in the mock transfected sample, but insufficient to interfere with analysis of the transfected PrP. (B)
Analysis of the detergent-insoluble fraction of either WT or mutant PrPs for glycosidase digestions. TRAPa in the detergent soluble fraction is shown
as a control for the digestions.
doi:10.1371/journal.ppat.1000479.g005
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(Golgi and post-Golgi) form represents ,40% of the total cellular
PrP at 30 minutes and is the predominant (.60%) form seen after
2 hours of chase. About half of this mature form was then
degraded over the course of the next 4 hours, consistent with an
approximate 6 hour half life of cell surface PrP observed in
previous studies [30].
PrP(H187R) looked qualitatively similar to wtPrP at early time
points, as no differences were noted in its core glycosylation and
initial trimming up to 30 minutes of chase (Fig. 7A). Mature
PrP(H187R) was also generated by 30 minutes, reaching a
maximal amount by 2 hours and decaying with similar kinetics
to wtPrP. The principal difference from wtPrP was that a small
proportion of the trimmed, immature form of PrP(H187R)
generated at 30 minutes persisted throughout the chase period
(Fig. 7A). This band decayed with kinetics slower than that of the
mature form, leading to a progressive increase in its relative
prominence. By the 6 hour chase point, this immature species
represented ,30–50% of total PrP(H187R), whereas it was largely
absent from wtPrP (see densitometry analysis, Fig. 7A). Analyses of
other globular domain mutants such as PrP(E200K) and
PrP(D178N) showed very similar results, while by contrast,
PrP(A117V) mirrored wtPrP and showed no persistence of an
immature species (Fig. S4A, S4B, and data not shown).
Thus, a normally transient, glycan-trimmed minor population
of immature PrP seen during the normal maturation of wtPrP
persists for a prolonged period during the biogenesis of several
globular domain mutants, but not a hydrophobic domain mutant.
The migration of this immature population corresponds to the
migration of the insoluble, intracellular, EndoH-resistant, mutant-
specific form characterized at steady state (Fig. 4). It is important
to note that while this persistent immature mutant-specific PrP
species represents a very small proportion of the total PrP
synthesized (,10–20%), its relatively long half-life compared to
the other PrP forms explains how this species can nonetheless
represent a sufficient population of total PrP at steady state to
allow detection by both immunoblotting and immunofluorescence.
We next addressed the location and nature of this minor
subpopulation of PrP over time by combining pulse-chase analysis
withassaysofsubcellularlocalization.Extracellulartrypsindigestion
at each time point during the pulse-chase showed that the mutant-
specific immature species, but not the mature species, was largely
shielded from the cell surface (Fig. 7B). Densitometric analysis of the
6 h chase point shows that the mature species was nearly fully
digested, while the immature species were mostly shielded. As
expected, the unglycosylated species was completely protected due
to its cytosolic localization. Glycosidase digestion showed that the
immature species becomes resistant to EndoH by 30 minutes of
chase, concomitant with the observed glycan trimming that likely
represents the action of cis-Golgi mannosidases (Fig. 7C). This
indicates that the mutant-specific species has exited the ER
(consistent with the analyses of PrP at steady state), but does not
acquire mature glycans or reach the cell surface efficiently.
Post-ER metabolism of misfolded mutant PrP
The rapid acquisition of EndoH resistance of the mutant-
specific immature species indicates that it passes the major
chaperone-based quality control systems in the ER without
significant impediment. This could be explained in two ways.
One possibility is that this species folds correctly when in the ER
environment (and hence, does not become a substrate of the QC
machinery), but misfolds upon delivery to the different environ-
ment of the Golgi. Alternatively, it might misfold in a manner that
is invisible to the ER QC systems, allowing its exit. In order to
Figure 6. Limited protease digestion analysis for folding status
of PrP mutants. Total detergent lysates of the indicated PrP
constructs were digested with various concentrations of trypsin on
ice before separation into soluble and insoluble fractions that were
analyzed by immunoblots. Note that these digestion conditions are
significantly milder than that used for analysis of surface exposure (e.g.,
in Fig. 4A and 5A), where trypsin fully digests the PrP mutants.
doi:10.1371/journal.ppat.1000479.g006
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analyses with assays of detergent insolubility.
Upon pulse labeling, when PrP is quantitatively in the ER (i.e.,
EndoH sensitive with untrimmed glycans), we could detect a
difference in relative solubility between wtPrP and PrP(H187R)
(Fig. 8A). As expected, PrP(H187R) displayed a larger proportion of
detergent insoluble PrPisoformsattheearliestpointofPrPbiogenesis
(,23%, compared to ,11% for wtPrP). This insoluble mutant PrP
population persisted during the 6-hour chase, while the soluble
population was converted into mature species. Similar results were
obtained for PrP(E200K) (data not shown). We therefore conclude
that the globular domain mutants of PrP display altered folding
immediately upon their synthesis and entry into the ER. However,
this subpopulation is neither recognized by ER quality control, nor
retained in the ER. Instead, it is fully competent for ER exit and
reaches the Golgi, where it is accessible to cis-Golgi glycosidases.
However, it fails to mature further, retains its altered folding status,
and does not reach the cell surface.
Figure 7. Immature mutant PrP species persist in post-ER intracellular compartments. (A) Pulse-chase analysis of cells expressing wtPrP
and PrP(H187R). Cells were pulsed for 10 minutes with
35S-methionine, chased for the times indicated (in hours) and total cell lysates were
immunoprecipitated for PrP. The asterisk (*) indicates lanes whose desitometric profile is shown below. (B) Cells expressing wtPrP or PrP(H187R) were
analyzed by pulse-chase analysis as described in panel A. Just prior to harvesting the cells, they were either treated with 100 mg/ml of extracellular
trypsin (+Trypsin) or were left untreated. The asterisk (*) indicates lanes whose densitometric profile is shown below. (C) Pulse (0 hours) and chase
(0.5 hours) samples from PrP(H187R) expressing cells were digested with EndoH (E), PNGase (P) or left untreated (2). Note that essentially all of the
PrP is converted from EndoH sensitive (at pulse) to resistant forms (at chase), including the immature forms (indicated by asterisk).
doi:10.1371/journal.ppat.1000479.g007
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specific species was not recognized by ER-based QC was provided
by the failure of this subpopulation to be degraded even upon
prolonged retention in the ER with Brefeldin A (Fig. 8B).
Furthermore, this species was not significantly stabilized upon
proteasome inhibition, the degradation pathway utilized by ER-
based QC (Fig. 8C). Remarkably however, this detergent insoluble
population of globular domain mutants is not intrinsically
refractory to ER-associated degradation (ERAD). In cells deficient
in GPI anchor addition (A4 cells), mutant PrPs become detergent
insoluble as in normal cells (Fig. 8D), yet are degraded
quantitatively from the ER by a proteasome-dependent retro-
translocation pathway [31]. Thus, this detergent-insoluble sub-
population of mutant PrPs is competent for retrotranslocation and
degradation; however, in normal cells, it is apparently misfolded in
a manner that makes it invisible to the ER-based QC pathways.
Misfolded PrP mutants are degraded in the endo-
lysosomal system
Despite exit from the ER, the immature mutant-specific
population of PrP does not reach the cell surface. Instead, it
appears to be slowly lost from cells by a proteasome-independent
pathway. Since the major non-proteasomal site of protein
degradation in the secretory pathway is in the lysosome, we
evaluated a role for acidic compartments in mutant PrP
metabolism. Perturbation of endo-lysosomal function with Bafilo-
mycin A1 (an inhibitor of the vacuolar type H
+- ATPase) led to the
steady-state enhancement of the mutant-specific detergent-insolu-
ble form of PrP(H187R) (Fig. 9A), suggesting the involvement of
acidic compartments in its turnover. This conclusion was further
confirmed by pulse-chase experiments, where we observed that the
immature species of mutant PrP was completely stabilized in the
presence of Bafilomycin A1 (Fig. 9B). Mature species of both
wtPrP and PrP(H187R) were also stabilized, as expected from
previous studies showing degradation of surface PrP by the endo-
lysosomal system. Thus, the loss of misfolded mutant PrP(H187R)
relies on acidic compartments, indicating that this species is either
degraded in lysosomes or excreted from the cell (e.g., on exosomes
or via secretory lysosomes).
To investigate how mutant PrP was being metabolized, we
analyzed both total protein and exosomes from the conditioned
media of PrP-expressing cells (Fig. 9C). A small but detectable
amount of mutant and wild type PrP were found in the media and
in exosomes from N2a cells. However, the amount recovered from
PrP(H187R) media was both slightly less than for wild type PrP,
Figure 8. PrP mutants pass ER quality control and are not degraded by proteasomes. (A) Pulse-chase samples from wtPrP and PrP(H187R)
expressing cells were separated into detergent soluble (S) and insoluble (P) fractions, immunoprecipitated, and analyzed by autoradiography. (B)
Pulse-chase analysis of wtPrP or PrP(H187R) expressing cells as in panel A, but in the presence of 10 mg/ml of Brefeldin A, an inhibitor of ER to Golgi
trafficking. (C) Pulse-chase analyses of wtPrP and PrP(H187R) in the absence or presence of 5 mM MG132, a proteasomal inhibitor. (D) A4 cells
expressing wtPrP or PrP(H187R) were separated into detergent soluble (S) and insoluble (P) fractions and analyzed by immunoblotting for PrP.
doi:10.1371/journal.ppat.1000479.g008
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0.1 mg/ml of Bafilomycin A1 or vehicle for 6 hours before analyzing total cell lysates by immunoblotting. (B) Pulse-chase analysis of cells expressing
wtPrP or PrP(H187R) in the absence (2) or presence (+)o f0 . 1mg/ml of Bafilomycin A1. Indicated chase samples were further fractionated into
detergent soluble (S) and insoluble (P) components. (C) Cells expressing wtPrP or PrP(H187R) were treated with Bafilomycin A1 or vehicle for 12 hours
before analyzing total cell lysates, the conditioned media, and exosomes by immunoblotting. Six-fold relative amount of the media and exosome
samples were analyzed. Two exposures of the blot are shown.
doi:10.1371/journal.ppat.1000479.g009
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upon Bafilomycin A1 treatment, the immature species of
PrP(H187R) accumulated inside cells to far higher levels than
seen in the media in the absence of Bafilomycin A1. This means
that essentially none of the PrP forms sensitive to Bafilomycin A1
inhibition are being lost via excretion from the cell. Thus, the
immature species of mutant PrP is metabolized intracellularly in a
manner dependent on acidic compartments. Consistent with this
conclusion, chloroquine (another lysosome alkalinizing agent) also
stabilized the glycosylated forms of PrP(H187R) (data not shown).
When considered together with the lack of proteasome involve-
ment (Fig. 8C), these results are consistent with a model in which
the subpopulation of misfolded mutant PrPs pass quality control
inspection at the ER but are segregated in a post-ER compartment
and routed to lysosomes for degradation.
A role for the N-terminus in mutant PrP metabolism
Interestingly, although the immature species of mutant PrPs are
trafficked to and degraded in lysosomes, this subpopulation neither
accumulates in this compartment nor colocalizes significantly with
lysosomal markers (such as Lgp-120) or lysotracker (data not
shown). This indicates that upon reaching the lysosome, its
degradation is probably relatively rapid (evidenced by its dramatic
stabilization upon Bafilomycin 1A treatment). Our data further
suggests that this mutant subpopulation traffics from the ER to
Golgi in under 30 minutes (Fig. 7A). Yet its overall half-life appears
to be at least as long as the mature form (,6 hours), suggesting that
in its trafficking from ER-Golgi-lysosome, the rate limiting step is
likely to be delivery from the Golgi to lysosome. Consistent with this
interpretation, the differentially localized mutant PrP is preferen-
tially enriched in a perinuclear region, which in earlier studies was
shown to co-localize with both Golgi and endosome markers [29].
Both of these compartments are major centers of protein sorting for
a wide variety of secretory and membrane proteins. Sorting is
typically mediated via sorting motifs that are recognized by their
respective receptors or adaptors.
To gain insight into the misfolding-selective sorting operating on
mutant PrP, we sought to identify potential sorting determinant(s)
by analyzing PrP deletion mutants. We found that deletion of
residues 23–48 (the DN constructs) markedly reduced the amount
of detergent-insoluble, immaturely glycosylated species of several
PrP mutants relative to their full length (FL) counterparts
(Fig. 10A). In most cases, this decrease was accompanied by a
relative increase in the fully mature, detergent-soluble species
(Fig. 10A). In all but the most severe mutant [e.g., PrP(D202N)],
deleting the N-terminal domain normalized the behavior in the
solubility assay to near wild type levels. Even for PrP(D202N), a
significant degree of normalization was observed. A predominantly
cell surface localization of the fully mature species for the DN
constructs was confirmed by both trypsin accessibility assays and
indirect immunofluorescence (data not shown).
Analysis of PrP(H187R) and PrP(H187R)DN by pulse-chase
showed that the DN construct generated mature PrP species in
amounts and kinetics very similar to wild type PrP (Fig. 10B; left
graph). The improved maturation efficiency of PrP(H187R)DN
was accompanied by a concomitant decrease in immature PrP
species (Fig. 10B; middle graph). This effect was not a consequence
of selective ER degradation of immature species of
PrP(H187R)DN as it was not stabilized by MG132 (Fig. 10B;
middle graph). As expected, the non-translocated PrP species in
the same samples were indeed stabilized by MG132, thereby
serving as a useful internal control (Fig. 10B; right graph). Thus, by
both steady state and pulse-chase analyses, deletion of the N-
terminal domain significantly modulates the maturation of several
PrP mutants, but has little or no effect on wtPrP.
Enhanced maturation of PrP(H187R)DN could transpire
because the N-terminal deletion either prevents the initial
misfolding of the C-terminal globular domain or prevents its
selective retention within the secretory pathway. At present, we
cannot fully discriminate between these possibilities. However, we
did observe that the detergent insolubility of pulse-labeled
PrP(H187R) was only partially improved by the N-terminal
deletion (Fig. 10C), even though subsequent maturation of
PrP(H187R)DN was essentially indistinguishable from wild type
PrP (Fig. 10A, 10B). Thus, improved generation of fully mature
species of PrP(H187R)DN cannot fully be explained by an effect
only on its initial folding in the ER. This may suggest that the N-
terminus could also have a role in modulating the intracellular
trafficking of mutant PrP though the secretory pathway, although
this remains to be investigated. Thus, two elements, a misfolded C-
terminal domain and the extreme N-terminus, collude to influence
the metabolism of PrP mutants.
In order to narrow the motif within this N-terminal domain that
influences the generation and/or metabolism of misfolded PrP, we
engineered a version of PrP(H187R) in which 3 highly conserved
lysineresidues(at positions23,24and27)werechanged toarginines
[PrP(H187R)-KR3].This constructwasthen quantitatively assessed
for localization using our single cell analyses (Fig. 11A). Remark-
ably, this conservative mutation led to a decrease in the amount of
intracellular PrP such that the relative cellular distribution of
PrP(H187R)-KR3 resembled that of wtPrP, while being statistically
different from that of PrP(H187R) (p=0.0006). Biochemical
analyses of PrP(H187R)-KR3 revealed the basis of this effect. We
found that in pulse-chase experiments, a higher proportion of
PrP(H187R)-KR3 was converted into mature forms at the expense
of immature species that normally predominate during the
biogenesis of PrP(H187R) (Fig. 11B). This is most readily seen at
the 30 minute chase point (see densitometry in Fig. 11B), where the
ratio of mature to immature species is significantly increased for
PrP(H187R)-KR3. Analysis of total glycosylated PrP species at
steady state for detergent solubility showed that the KR3 mutation
reduced the percent of insoluble species for each of several mutants,
albeit to somewhat different levels, and to a lesser degree than the
DN deletions (Fig. 11C). Thus, the N-terminus, and in particular a
lysine-based motif, appears to be involved in the fate of several
mutant PrPs by influencing either their initial biosynthesis and/or
their subsequent intracellular trafficking.
Discussion
We have quantitatively analyzed the trafficking and metabolism
of disease-causing PrP mutants. Our aims were two-fold. First, we
hoped to gain insight into the QC pathways that discriminate wtPrP
from mutants that are ostensibly prone to misfolding. Second, we
wanted to determine whether many or all of the PrP mutants would
share certain features in their metabolism that could represent
potential pathways of direct importance to disease pathogenesis. By
determining how cells metabolize PrP mutants relative to the wild
type counterpart, we discovered a prominent role for post-ER
pathways of differential sorting and trafficking. Interestingly, we
found that despite the multitude and diversity of ER quality control
pathways, all of the PrP mutants we analyzed were refractory to
recognition by these components. They are instead recognized in a
more distal compartment of the secretory pathway and sorted for
degradation in lysosomes. The implications of these findings for
inherited and transmissible prion disease as well as cellular quality
control in general are discussed in turn below.
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Our primary conclusion that disease-causing PrP mutations use
a QC pathway that culminates in lysosomal degradation has
several potential implications for inherited prion disease patho-
genesis. The most important is that reduced lysosomal function
would lead to accumulation of misfolded PrP species. This could
represent a mechanism of neuronal cytotoxicity in inherited prion
disease. Indeed, age-dependent changes in the lysosomal system
such as decreased activity of lysosomal hydrolases and decreased
regulation of lysosomal pH have been documented [32]. Such
alterations have been proposed to contribute to the slow and age-
dependent progression of various protein misfolding disorders
including Alzheimer’s disease and Parkinson’s disease [33–35],
and could also contribute to the pathogenesis of inherited prion
diseases.
In addition, increased production of misfolded PrP species may
lead to saturation of the trafficking pathway from the trans-Golgi
network (TGN) to lysosomes. It is unlikely that this pathway is used
solely by PrP as most cellular trafficking and QC systems have a
wide range of substrates. This means that increased traffic of
misfolded PrPs (as would occur with these mutants) could lead to
compromised function of the secretory pathway, saturation of the
Golgi QC machinery, and/or inappropriate secretion of immature
or misfolded cellular proteins. In addition, sorting of lysosomal
enzymes that are critical for the degradative capacity of this
compartment could be compromised. This would lead to reduced
lysosomal activity, perhaps in an age-dependent manner [32],
thereby causing increased accumulation of aberrant PrP species
(and other cellular substrates) within the lysosome. Undegraded
misfolded PrPs in the lysosome may further exacerbate lysosomal
dysfunction. Indeed decreased function of lysosomal cysteine
proteases has been shown to be associated with misfolded PrP
accumulation in prion disease [36,37]. Additionally, scrapie
infected neurons have been shown to accumulate large numbers
Figure 10. The N-terminus of PrP modulates mutant PrP metabolism. (A) The full length (FL) or N-terminally deleted (DN, lacking residues 23–
48) constructs for wild type and mutant PrPs were analyzed by the detergent solubility assay. In each case, deletion of the N-terminus resulted in
decreased insoluble forms. A corresponding increase in the fully mature soluble form is apparent in most cases. (B) Pulse chase analyses (as in Fig. 7A)o f
wtPrP, PrP(H187R), wtPrPDN and PrP(H187R)DN were quantified by phosphorimaging. The left panel plots the appearance of fully mature species (as a
proportion of total PrP) over time. The middle panel shows the time course of disappearance for immature glycosylated species (plotted as a percent of
the amount present at pulse). The inclusion of 5 mM MG132, a proteasome inhibitor, had no effect on the immature species for PrP(H187R)DN. The right
panel shows the fate of unglycosylated PrP, without or with 5 mM MG132. (C) Lysates harvested after pulse labeling with S
35-methionine from cells
expressing wtPrP, wtPrPDN, PrP(H187R) and PrP(H187R)DN were separated into detergent soluble (S) and insoluble (P) fractions, immunoprecipitated,
and analyzed by autoradiography. The percent of labeled PrP that is insoluble is indicated below the respective panels.
doi:10.1371/journal.ppat.1000479.g010
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brain [38]. Thus, lysosomal dysfunction could be a shared
contributing event in both familial and transmissible prion
diseases.
Lysosomal trafficking could also play a role in the spontaneous
conversion of some mutant PrPs into the PrP
Sc isoform. While not
all inherited PrP mutants generate infectivity (e.g., A117V), a few
mutants (e.g., E200K or D178N) are unambiguously converted to
PrP
Sc. Lysosomes (or related acidic compartments) have long been
implicated as the site of conversion of PrP
C to PrP
Sc during
transmissible prion disease [30,39,40], suggesting that this
environment may be especially conducive to PrP misfolding or
re-folding. It is therefore plausible that routing of misfolded
mutant PrPs to acidic compartments when combined with
decreased lysosomal degradation (as might occur during aging),
may favor its spontaneous conversion to PrP
Sc.
Quality control in the Golgi versus the ER
Our data indicate that wild type and mutant PrPs are
distinguished and trafficked differentially within the cell after they
have left the ER, the predominant site of QC in the secretory
pathway. This conclusion is consistent with several previous
observations providing evidence for altered mutant PrP species in
post-ER intracellular compartments on the basis of imaging,
glycosylation analysis, or inhibitor studies [14,27,41,42]. However,
many studies have implicated ER-based QC and degradation as
the major route for mutant PrP metabolism. These latter studies
have largely relied on two types of observations, each of which
merits closer scrutiny. First, mutant PrPs have typically been
observed to be ER-localized (at least partially retained), suggesting
engagement of ER QC pathways [15,17,27]. In some instances,
interactions with chaperones have also been observed [15]. What
has been unclear in such studies is how quantitative or uniform the
retention is, and whether it is dependent on overexpression. In
some instances, viral-based expression at very high levels may
explain the observations. Indeed, we too observe some cells in our
experiments that show ER localization (Fig. S1), often in the
highest expressing cells. However, this was not consistent across all
expression levels, in contrast to the post-ER population we
describe here.
The second line of evidence for ER-based QC is the
accumulation of unglycosylated PrP upon prolonged proteasome
inhibition [16,43,44]. However, PrP translocation was later found
to be partially inefficient [9,24,29], indicating that at least some
unglycosylated PrP is generated from non-translocated material.
In addition, translocation of PrP is decreased even further during
ER stress [10,45], which is a secondary consequence of
proteasome inhibition. More importantly, when translocation
efficiency is improved, the proteasome inhibitor-dependent
accumulation of unglycosylated PrP could be completely prevent-
ed [10,29]. This argues strongly for unglycosylated cytosolic
species being generated primarily, if not exclusively from
inefficient forward translocation and not ER-based QC. Further-
more, a precursor-product relationship between ER lumenal PrP
and cytosolic PrP has never been shown formally by pulse-chase
studies in cases where ER-based QC of PrP mutants has been
proposed. This is in contrast to our direct demonstration of ER-
based QC and retrotranslocation of PrP in GPI-anchoring
deficient cells [31]. We therefore believe that we would have
detected ER-associated degradation of mutant PrPs by these same
assays if it were occurring to any appreciable degree. Instead, we
favor a model of mutant PrP QC involving post-ER compartments
of the secretory pathway, potentially the Golgi. It is interesting to
note that different forms of PrP use distinct pathways for their
disposal, ranging from ERAD, cytosolic QC, and lysosomal
degradation. Among these, the post-ER pathway described here
seems to be shared among many of the C-terminal globular
domain mutants.
The existence of Golgi-mediated QC was first suggested by
studies in yeast showing that certain mutants of plasma membrane
proteins were retained in the Golgi and degraded in the vacuole
[46,47]. Other studies in yeast using heterologous lumenal proteins
have implicated a transmembrane protein (Vps10p) as one of the
recognition receptors for misfolded proteins within the Golgi [48].
However, analogous Golgi-based QC pathways in mammalian
cells have been poorly characterized at present. One example may
be the T-cell receptor, whose final assembly occurs within the
Golgi. Incomplete TCR complexes have been shown to be
retained in the TGN and targeted for lysosomal degradation [49].
Another example may be the Golgi enzyme Furin, aggregates of
which are recognized within the Golgi and targeted for
degradation in lysosomes [50]. Both of these studies suggested
that multimeric status may be a determinant in Golgi-based QC.
Results from our current study are consistent with a similar
model, suggesting that PrP may use a more general QC pathway
that remains to be studied in detail. Of crucial importance is the
machinery and recognition motifs on mutant PrPs used to
discriminate folded from misfolded molecules. While additional
studies are required to answer this question, the currently available
information suggests an intriguing hypothesis. Many PrP muta-
tions may act by favoring dimerization or multimerization of PrP
molecules without grossly affecting the overall protein fold. This
could explain why ER QC pathways fail to recognize misfolded
mutant PrPs. However, this multimerization could create novel
motifs (potentially involving the N-terminal lysines) that are
recognized by sorting factors in the ER, ERGIC or Golgi, as
has been suggested for Furin [50]. This hypothesis is supported by
studies using the symmetrical compound, Suramin, whose bivalent
interaction with the C-termini of PrP might allow the N-termini to
interact with lysosomal routing factors [51–53]. The identification
of such putative sorting factors is an important goal of our ongoing
studies. Misfolded mutant PrPs could serve as an important
physiologically relevant model system for dissection of the
molecular components of such post-ER QC pathways.
Materials and Methods
Constructs, cells and reagents
All PrP constructs are based on human PrP. This is recognized
by the 3F4 monoclonal antibody, which does not recognize mouse
Figure 11. Conserved Lysines in the N-terminus modulate the fate of PrP mutants. (A) Single-cell quantification of localization as in Fig. 2
was performed on cells expressing wtPrP (blue) , PrP(H187R) (red) and PrP(H187R)-KR3 (green), construct in which three conserved Lysines in the N-
terminus were changed to Arginines. PrP(H187R) was statistically different from wtPrP (*, p=.003), and PrP(H187R)-KR3 was statistically different from
PrP(H187R) (**, p=.0006). (B) Pulse-chase analysis of cells expressing PrP(H187R) and PrP(H187R)-KR3, performed as in Fig. 7A. The asterisks indicate
lanes whose desitometric profile is shown below. (C) Cells expressing the indicated constructs either lacking or containing the KR3 mutation in the N-
terminus were analyzed by the detergent solubility assays as in Fig. 10A. The percent of each construct in the detergent-insoluble pellet was
quantified and plotted.
doi:10.1371/journal.ppat.1000479.g011
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generated by site-directed mutagenesis and the mutation verified
by sequencing. The data shown are from human PrPs containing a
Valine at position 129, although very similar results were observed
for the Methionine variant. Human wtPrP, all mutant PrPs, and
fluorescent protein (FP) tagged PrPs were subcloned into and
expressed from pCDNA3.1-based vectors (Invitrogen, Carlsbad,
CA) by standard procedures. FPs were the monomeric variants of
CFP, GFP, and YFP. FP tagged PrPs were created by insertion of
PCR amplified FPs (Clontech, Mountain View, CA) into the
Bsu36I site in PrP (at residue 50). The monomeric Cerulean and
Venus variants of CFP and YFP were used. Co-localization with
ER was carried out using GFP-KDEL [54], which contains an
ER-targeting signal at the N-terminus, and an ER-retention signal
at the C-terminus. Lysosomal co-localization was carried out using
either RFP-Lgp-120 (a kind gift from Dr. J. Lippincott-Schwartz)
or Lysotracker. TGN and endosomes were visualized using CD-
MPR-GFP (a kind gift of Dr. J. Bonifacino). Culture and
maintenance of N2a, HeLa, and A4 cells was as described
[10,29,31]. All experiments involving transient transfections were
performed using either Lipofectamine 2000 (Invitrogen) or
Effectene (Qiagen, Valencia, CA) as per manufacturer’s instruc-
tions and cells were analyzed 18–24 hours post-transfection. For
Lipofectamine, 2 mg DNA was used per 35 mm dish; for
Effectene, 0.4 mg was used. The 3F4 mouse monoclonal antibody
against PrP was purchased from Signet Laboratories (Dedham,
MA). Brefeldin A, MG132 and Bafilomycin A1 were from EMD
Biosciences (La Jolla, CA). Trypsin and Trypsin inhibitor were
purchased from Sigma (St. Louis, MO). EndoH and PNGase were
from New England Biolabs (Beverly, MA) as were all enzymes
used in cloning procedures.
Biochemical assays
Detergent solubility assays, glycosidase digestions, pulse-chase
analysis, immunoblotting, and immunoprecipitations have been
described [10,29,31]. Briefly, cells were washed with 16PBS and
lysed in ice-cold detergent buffer (DB) containing 150 mM NaCl,
50 mM Tris, pH 7.4, 2 mM EDTA, 0.5% Triton X-100, and
0.5% Deoxycholate. After passage through a 22-guage needle
several times, the samples were centrifuged for 30 min at 4uCa t
13,000 rpm in a microcentrifuge. Most transfections included ER-
localized GFP plasmid (usually comprising one-fifth of the total
transfected DNA) to verify that transfection efficiencies were both
uniform and greater than 50%. The GFP produced from this
marker was also useful in fractionation studies because it served as
a transfection control, loading control, and fractionation control:
in all experiments, we re-probed the blots with anti-GFP to
confirm equal expression, and quantitative recovery in the
detergent soluble fraction (data not shown). In addition, all blots
were stained for total protein to verify equal loading (data not
shown). In experiments where total lysates were analyzed, all
cellular material was fully solubilized by boiling in 1% SDS, 0.1 M
Tris, pH 8 and processed further for SDS-PAGE. Metabolic
labeling, pulse-chase analysis and immunoprecipitations were
performed as detailed previously [10,29,31]. In experiments where
total PrP was being analyzed, cells at each time point were fully
solubilized in 1% SDS, 0.1 M Tris, pH 8, boiled, and processed
further for immunoprecipitation. In experiments where cells were
first fractionated, the cells were harvested in DB, separated into
supernatant and pellet fractions, and each fraction was solubilized
in SDS, boiled, and immunoprecipitated. The glycan modification
of PrP was assessed using EndoH and PNGase digestions on fully
denatured cell lysates, as previously described [31]. Where
indicated in pulse-chase experiments, inhibitors were added
30 min (10 mg/ml Brefeldin A or 0.1 mg/ml Bafilomycin A1) or
2 hours (5 mM MG132) prior to pulse labeling and maintained
during the chase. For steady state inhibitor experiments, inhibitors
were maintained in the culture media throughout the experiment.
For surface trypsin digestion, cells washed with 16 PBS were
incubated for 10 min at 24uC with 100 mg/ml trypsin in NaHM
buffer (150 mM NaCl, 20 mM HEPES, 2 mM MgOAc2). Trypsin
Inhibitor was added to 250 mg/ml, and after 2 min, the cells
sedimented by centrifugation, and lysed in detergent as above for
further analysis. As a control, detergent (0.2% Triton X-100) was
included during the trypsin digestion of a parallel sample to rule
out any intrinsic protease resistance of PrP under these conditions.
Limited trypsin digestion to assess PrP folding status was
performed on total detergent lysates prepared in ice-cold DB.
Trypsin was added to the indicated final concentrations from 10 to
100 mg/ml, and incubated for 60 min on ice. Trypsin inhibitor
was added to 500 mg/ml, incubated for 5 min on ice, and the
samples separated into soluble and insoluble fractions by
centrifugation for 30 min in a microcentrifuge at 4uC. 56 SDS-
PAGE sample buffer was added to the supernatants and pellets for
analysis by immunoblotting. For analysis of total PrP excretion,
transfected cells were placed into Opti-MEM media containing or
lacking 250 nM Bafilomycin A1 16 h after transfection. After
culturing for another 12 h, the conditioned media was collected,
debris removed by centrifugation for 2 min in a microcentrifuge at
full speed, and the supernatant subjected to TCA precipitation to
collect all of the proteins. The precipitated proteins were washed
in acetone, and dissolved in SDS-PAGE sample buffer. To isolate
exosomes, conditioned media (prepared as above) was centrifuged
for 2 min at full speed in a microfuge to remove debris. The
supernatant was then subjected to ultracentrifugation at
70,000 rpms in a TLA100.3 rotor with microtest tube adaptors.
The pellet containing exosomes was dissolved in SDS-PAGE
sample buffer. SDS-PAGE resolution of proteins was performed
on 12% Tris-Tricine gels. Quantification was by either phosphor-
imaging or densitometry. Where densitometry was used, multiple
exposures of the gels/blots were obtained and those in the linear
range of the film were used. Pulse-chase data was quantified using
a Typhoon Phosphorimager and company software (Molecular
Dynamics, Sunnyvale, CA) and autoradiographs were digitized
using Adobe software (San Jose, CA).
Fluorescence microscopy and quantitative image
analysis
Indirect immunofluorescence and confocal microscopy was as
before [29,31]. Briefly, images were obtained on a confocal
microscope (Zeiss LSM510; Carl Zeiss Microimaging, Thorn-
wood, NY) using the manufacturer’s image acquisition software.
All images were acquired using a 636oil objective and as 1 Airy
unit confocal slices (corresponding to roughly 1 mm thick slice). For
indirect immunofluorescent localization of PrP, 3F4 antibody was
used at 1:500 dilution and Alexa-dye conjugated secondary
antibody (Alexa-488 or Alexa-546; Invitrogen) was used at
1:1000 dilution [29]. Single-cell quantitative image analysis is
described in detail in Fig. S2. Statistical comparisons between
different constructs used the two-tailed Student’s t-test. The
ratiometric analysis was performed using NIH image software. A
macro was written to divide the image into 464 pixel regions. The
ratio of fluorescence in the green and red channels was calculated
for each region containing fluorescence signal above background.
This ratio, ranging from 0.1 to 10, was re-scaled to values from 0–
255 and plotted into a new image. This ratiometric image was
then pseudocolored using the rainbow scale look-up-table.
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Figure S1 Mutant and wtPrPs occupy heterogeneous but similar
cellular locales. (A) Indirect immunofluorescent detection of wtPrP
reveals considerable heterogeneity in localization patterns, three of
which are shown: predominantly cell surface (left), significant
perinuclear in addition to cell surface (middle), and surface,
perinuclear, and ER/nuclear envelope. (B) PrP(H187R) analyzed
as in panel A also show comparable heterogeneity. The percent
intracellular PrP for each cell (quantified in Fig. S2) is indicated in
the lower left of the images. (C) Single channel and merge images
of cells co-expressing fluorescently tagged wtPrP and PrP(H187R)
grown in the presence of 10 mg/ml of Brefeldin A for 8 hours. The
two proteins were found to co-localize throughout the ER, without
any obvious areas of segregation.
Found at: doi:10.1371/journal.ppat.1000479.s001 (1.22 MB TIF)
Figure S2 Image analysis for quantitation of total and
intracellular PrP. To quantify the surface and intracellular
populations of PrP on a per-cell basis, random fields (chosen
blindly using a co-transfected RFP marker) of PrP-expressing cells
were first imaged under multiple detector conditions (typically
three of four) that allow imaging of cells with expression levels
spanning ,25 fold (see example in panel A). Each image is a 1 mm
thick confocal section focused at roughly the mid-nuclear level.
Each cell was quantified from the respective image in which the
fluorescence intensity of that cell falls entirely within the linear
range of the detector setting (i.e., the brightest cells are quantified
from Exposure 1, and the dimmest from Exposure 4). Regions of
interest (see example in panel B) were drawn around the cell
periphery (to quantify total fluorescence), and just within the
plasma membrane (to quantify intracellular fluorescence). After
subtracting background, raw values were obtained for the total,
intracellular, and surface (total minus intracellular) fluorescence.
These values were normalized for the detector setting used so that
values obtained from cells quantified from different exposures
could be directly compared. The normalized values were than
used to calculate the % intracellular and surface-to-intracellular
parameters that are plotted in Fig. 2, 3, and 11. It should be noted
that this method of quantification typically underestimates the
surface population of PrP relative to the intracellular population.
This is because the top and bottom surfaces are never accurately
imaged, the latter of which contains substantial surface area. Thus,
the average value obtained by imaging gives ,70–75% surface
PrP, while biochemical analyses of the same cell population gives
,90–95% (as judged by trypsin accessibility). Nonetheless, the
single-cell analyses allow direct comparisons to be made among
various constructs since the systematic source of error is uniform.
Similarly, choosing to quantify a single arbitrary confocal section
risks missing significant sources of intracellular fluorescence that
are out of the plane of focus. However, this again is a systematic
error that is averaged out by the analysis of many cells, and applies
uniformly to all constructs analyzed. Thus, as shown in Fig. 2,
systematic differences are revealed upon analyses of sufficient cells.
More importantly, because expression level data are included in
this analyses, the effect of this variable can be analyzed more
readily than in biochemical assays performed on cell populations.
Found at: doi:10.1371/journal.ppat.1000479.s002 (1.68 MB TIF)
Figure S3 Heterogeneity in wtPrP and mutant PrP behavior. (A)
Cells were transiently transfected with wtPrP or PrP(E200K) using
either Lipofectamine (2 mg DNA) or Effectene (0.4 mg DNA)
transfection methods. The soluble (S) and insoluble (P) fraction of
the detergent lysates were immunoblotted for PrP. The two blots
are taken from the same exposure and processed in parallel,
illustrating the markedly different expression levels. The migration
of different PrP species are indicated on the left as in Fig. 4. Note
that in both cases, increased insoluble, immature species are seen
for E200K relative to wtPrP. Parallel blots with an antibody that
also recognizes endogenous PrP showed that expression of
exogenous PrP transfected with Effectene is comparable to
endogenous PrP (data not shown). (B) Cells were transiently co-
transfected with GFP and either wtPrP or PrP(H187R) in varying
ratios and detergent lysates resolved by SDS-PAGE were
immunoblotted for PrP. 1=Ratio of 4:1 PrP:GFP; 2=Ratio of
2.5:2.5 PrP:GFP; 3=Ratio of 1:4 PrP:GFP. The migration of
different PrP species is indicated on the left and molecular weight
markers are shown on the right. Both faint and dark exposures are
shown. Note that while there is an expression level dependent
increase in the amount of misfolded (insoluble) PrP in PrP(H187R)
expressing cells, this mutant-specific property remains distinguish-
able at the lowest expression levels, which we estimate to be
comparable to normal endogenous PrP. (C) Detergent lysates from
cells transiently transfected with wtPrP or PrP(H187R) were
immunoblotted for PrP. The left and right panels show results
from 2 separate experiments on cultures of different passage
numbers to demonstrate that despite heterogeneity between
individual experiments, the amount of PrP(H187R) forms
recovered from the insoluble fraction was consistently greater
than that recovered in the analogous fraction for wtPrP. The most
subtle difference we have observed in any experiment is shown in
the left panel, while a more typical result is shown in the right
panel. Similar heterogeneity was also seen with other mutants.
The basis of this heterogeneity remains unclear, and cannot fully
be explained by expression level effects alone.
Found at: doi:10.1371/journal.ppat.1000479.s003 (0.88 MB TIF)
Figure S4 Pulse-chase analysis of PrP(E200K) and PrP(A117V).
The metabolism of E200K (panel A) and A117V (panel B) were
compared to wtPrP by pulse-chase analysis exactly as in Fig. 7A.
Normalized densitometric analysis of the lanes indicated by the
asterisks is shown below the autoradiographs. Note that the
immature forms are enhanced at the expense of mature forms for
E200K.Very similar results were alsoobtained for D178N (data not
shown) and H187R (Fig. 7A). By contrast, A117V looks very similar
to wtPrP in its metabolism. Note also that wtPrP looks slightly
different in the two experiments (which were done on different
days), potentially due to different expression levels (see Fig. S3).
Found at: doi:10.1371/journal.ppat.1000479.s004 (0.36 MB TIF)
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